Ensho Therapeutics unveils new data on NSHO-101 as once-daily treatment for inflammatory bowel disease
Ensho Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing oral therapies for inflammatory diseases, has presented promising new data on NSHO-101, a novel once-daily ... Read More
Teva and Sanofi reveal promising Phase 2b data for duvakitug in ulcerative colitis and Crohn’s disease
Teva Pharmaceutical Industries Ltd. and Sanofi have unveiled encouraging new data from their Phase 2b RELIEVE UCCD trial, highlighting the potential of duvakitug, a novel ... Read More